OptimizeRx Corporation is a digital healthcare technology company that provides data-driven marketing solutions for life sciences organizations. Founded in 2006, the company connects pharmaceutical brands with healthcare providers and patients through an omnichannel network embedded in electronic health record and ePrescribing platforms. Its core offerings include the Dynamic Audience Activation Platform for predictive analytics and audience identification, and Micro-Neighborhood Targeting, a privacy-centric direct-to-consumer solution acquired via the 2023 purchase of Medicx Health. The company also provides Profiler for audience insights and Pharmacy Alerts to support prescribing workflows. OptimizeRx serves life sciences clients in the United States, facilitating engagement across channels such as programmatic display, connected television, social media, and email.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Information Technology Services Homepage optimizerx.com
Sector Technology IR page optimizerx.com
Tags
healthcare marketing, precision marketing, audience targeting, direct-to-consumer, pharmaceutical marketing, data analytics, machine learning, omnichannel marketing, Dynamic Audience Activation Platform, Micro-Neighborhood Targeting, Profiler, Pharmacy Alerts, Medicx Health
Press page —

Metrics

Valuation  
Market cap $ 157.871M
Market cap (USD) $ 157.871M
P/E 32.12
PEG —
P/BV 1.18
P/S 1.68
P/OCF 7.91
P/FCF 7.94
Dividend yield —
Turnover / mcap —
Returns  
ROE 4.2%
ROI 3.3%
ROIC 5.6%
Profit margin 4.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity 9.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 109.429M 92.127M 71.522M 1.025M 61.293M 43.313M 24.598M 21.206M 12.127M 7.751M 7.221M 6.503M 4.957M 2.049M 1.112M 71.065K — —
Net profit 5.132M -20.11M -17.566M -11.438M 378.079K -2.207M -3.143M 226.344K -2.104M -1.539M -595.14K -1.025M 215.847K -363.976K -2.121M -2.009M — —
Free cash flow 18.657M 4.777M -7.326M 10.573M 625.717K -6.378M -1.749M 758.193K -1.522M -644.399K 513.064K -63.334K 1.133M -626.263K -534.609K -1.313M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 12.26 4.86 14.31 16.8 62.11 31.16 10.27 10.97 1.21 0.8 1.26 0.88 1.75 — — 1.25 — —
Price performance 12m 1.52 -0.66 -0.15 -0.73 0.99 2.03 -0.06 8.07 0.51 -0.37 0.43 -0.5 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.06M 2.26M 6.46M 7.42M 17.9M 24.8M 22.2M 36.3M 38.2M 37.8M
↳ YoY growth +7.5% -26.2% +186.1% +14.9% +141.1% +38.7% -10.7% +63.6% +5.4% -1.2%
↳ 5y CAGR +32.7% +28.7% +44.4% +52.0% +57.9% +41.2% +38.8% +16.1%
Borrowings, current (USD) — — — — — — — 2M 2M 4.26M
Borrowings, non-current (USD) — — — — — — — 34.2M 30.8M 21.4M
Lease liabilities (USD) — — 465,000 564,184 448,753 327,708 234,434 593,063 377,000 427,000
Cash and deposits (USD) 7.03M 5.12M 8.91M 18.9M 10.5M 84.7M 18.2M 13.9M 13.4M 23.4M
Intangible assets (USD) 772,394 638,766 2.77M 2.55M 12.1M 10.6M 13M 49.4M 45.5M 40.8M
Right-of-use assets (USD) — — 462,000 559,863 445,974 328,820 235,320 572,895 366,000 404,000
Net debt (borrowings + leases - cash) (USD) — — — — — — — 23M 19.8M 2.74M
Cash flow detail
Operating cash flow (USD) -465,965 -1.48M 792,555 -1.66M -6.31M 726,039 10.7M -7.24M 4.89M 18.7M
Purchases of property, plant and equipment (USD) -178,434 -42,243 -34,362 -87,717 -68,041 -100,322 -81,005 -87,073 -112,000 -58,000
Purchases of intangible assets (USD) -163,836 — -56,651 -1.5M -11,932 -21,511 -163,560 — — —
Change in receivables (cash effect) (USD) -212,946 -305,465 -2.79M -628,830 -10.7M -6.99M 2.28M -8.71M -2.17M 460,000
Change in payables (cash effect) (USD) -205,977 88,075 -83,319 -46,249 125,255 -11,442 943,171 -1.32M -72,000 -520,000
Share buybacks (cash effect) (USD) -806,915 -390,000 — — — — -20M -7.52M — —
Interest paid (cash effect) (USD) 0.00 — — — — — — -1.21M -6.2M -4.18M
Income taxes paid (cash effect) (USD) 0.00 — — -897,960 — — — -48,222 -161,000 -1.76M
Share-based compensation (USD) 175,175 87,375 1.86M 2.26M 3.17M 5.49M 15.7M 13.7M 11.5M 6.96M
Operating cash flow before change in receivables (USD) -253,019 -1.17M 3.58M -1.03M 4.36M 7.72M 8.37M 1.47M 7.06M 18.3M
Free cash flow (OCF - PPE - intangibles) (USD) -644,399 -1.52M 701,542 -3.25M -6.39M 604,206 10.4M -7.33M 4.78M 18.7M
Income detail
Research and development expense (USD) — — 0.00 1.6M 0.00 — — — 0.00 0.00
Provision for credit losses (USD) 0.00 0.00 0.00 80,000 200,000 80,000 363,512 665,973 208,000 0.00
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.0% 0.0% 1.2% 1.6% 0.4% 1.5% 2.3% 0.6% 0.0%
Reported Mar 8, 2018 Mar 8, 2018 Mar 26, 2020 Mar 26, 2020 Feb 28, 2022 Feb 28, 2022 Mar 10, 2023 Apr 15, 2024 Mar 12, 2026 Mar 12, 2026

Operating KPIs — years

KPI Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net revenue retention (%) 121.0% 120.0% 116.0% 110.0% 90.0% 83.0%
Reported Aug 7, 2025 Nov 6, 2025 Mar 5, 2026 May 12, 2026 Aug 12, 2026 Nov 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

-Q3 revenue totals $21.6 million

-Q3 net income and adjusted EBITDA of $1.2 million and $6.3 million

-2026 revenue guidance updated to $87-$93 million; adjusted EBITDA guidance unchanged at $21-$25 million

-Repaid $9.3 million in debt principal since June 30, 2026, reducing current outstanding principal to $10.4 million

WALTHAM, MA. – November 11, 2026 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.

Financial Highlights

•Revenue decreased 17% to $21.6 million in Q3 2026, compared to $26.1 million in Q3 2025.

•GAAP net income of $1.2 million or $0.06 per basic and diluted share in Q3 2026, compared to GAAP net income of $0.8 million, or $0.04 per basic and diluted share, in Q3 2025.

•Non-GAAP net income of $3.8 million, or $0.20 per diluted share in Q3 2026, compared to Non-GAAP net income of $3.1 million or $0.16 per diluted share, in Q3 2025. (See *Non-GAAP Measures below)

•Adjusted EBITDA of $6.3 million in Q3 2026 compared to $5.1 million in Q3 2025.

October 28, 2026 at 7:30 AM EDT

PDF Version

WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, will hold a conference call on Wednesday, November 11, 2026, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2026. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

| Date: | Wednesday, November 11, 2026 |

| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |

| Toll Free: | 1-877-407-9716 |

| International: | 1-201-493-6779 |

| Conference ID: | 13763502 |

| Call me™ Link: | https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6 |

| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1780405&tp_key=07d90b8ba4 |

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the investors section of the OptimizeRx website at https://investors.optimizerx.com/.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

October 27, 2026 at 7:30 AM EDT

PDF Version

Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows

WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a healthcare technology company helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced a new partnership with PulsePoint, an award-winning programmatic platform advancing omnichannel healthcare marketing, that will make OptimizeRx’s authenticated electronic health record (EHR) and e-prescribing inventory available to PulsePoint clients.

The integration builds on both companies’ efforts to make HCP media more connected. OptimizeRx is expanding programmatic access to point of care inventory that historically was only purchased through direct or specialized channels, while PulsePoint brings that inventory and 250,000 incremental NPIs into its platform designed to coordinate HCP media activation, optimization, and reporting. Together, the companies are making point of care easier to incorporate into the broader media plan rather than managing it as a separate buy.

Reducing Fragmentation Across the HCP Media Plan

The partnership helps close a longstanding gap in omnichannel HCP marketing. Digital HCP media can build awareness and consideration over time. The EHR adds a lower-funnel layer closer to prescribing, delivering relevant information within the clinical workflow. Yet EHR media has historically been planned and purchased separately from other digital channels. By bringing OptimizeRx inventory into PulsePoint, marketers can more easily extend broader HCP campaigns into EHR and e-prescribing workflows within a connected programmatic strategy.

“Omnichannel gets harder when high-value channels live in separate buying environments,” said Stephen Silvestro, CEO of OptimizeRx. “Our work with PulsePoint removes a layer of fragmentation, making it easier for brands and agencies to put point of care to work alongside the rest of their media investments.”

“OptimizeRx extends the scale of in-workflow EHR engagement we can offer clients to fuel their comprehensive omnichannel HCP strategies,” said Keith Matt, Group Vice President of Sales at PulsePoint. “Paired with our broader EHR footprint and real-time activation, optimization, and reporting, clients get more reach, more control, and clearer visibility across every campaign.”

Extending Programmatic Reach at the Point of Care

PulsePoint is among the first DSPs to integrate OptimizeRx’s authenticated EHR inventory since OptimizeRx opened its network to programmatic buying in June 2026. The integration will give PulsePoint clients access to incremental NPIs through OptimizeRx’s point of care network and bring PulsePoint’s programmatic EHR reach to over 1 million NPIs. OptimizeRx’s authenticated EHR inventory is expected to be available to advertisers using PulsePoint in November 2026.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

Prompts

OptimizeRx Corporation (ticker OPRX), listed in United States.

ETFs Holding OptimizeRx Corporation

ETF Weight in ETF Shares Market value As of
SQLV 0.23% 11,368 $ 65.025K Jun 30, 2026
PSC 0.02% 67,360 $ 385.299K Jun 30, 2026
DFSV 0.01% 310,234 $ 2.752M Nov 12, 2026
DFAS 0.00% 18,709 $ 165.949K Nov 12, 2026
DCOR 0.00% 1,149 $ 10.192K Nov 12, 2026
AVSC 0.00% 9,470 $ 62.881K Nov 16, 2026